A cryptic pocket in Ebola VP35 allosterically controls RNA binding
暂无分享,去创建一个
Gregory R. Bowman | Maxwell I. Zimmerman | Justin R. Porter | Sukrit Singh | Gaya K. Amarasinghe | G. Bowman | J. Porter | Sukrit Singh | G. Amarasinghe | Katelyn E. Moeder | M. I. Zimmerman | Thomas E. Frederick | Neha Vithani | Matthew A. Cruz | N. Vithani | M. A. Cruz | U. L. Mallimadugula
[1] J Andrew McCammon,et al. Discovery of a novel binding trench in HIV integrase. , 2004, Journal of medicinal chemistry.
[2] G. Oakley,et al. In silico and in vitro methods to identify ebola virus VP35-dsRNA inhibitors. , 2016, Bioorganic & medicinal chemistry.
[3] Navid Dianati,et al. Unwinding the "hairball" graph: a pruning algorithm for weighted complex networks , 2015, Physical review. E.
[4] J. M. Binning,et al. Basic Residues within the Ebolavirus VP35 Protein Are Required for Its Viral Polymerase Cofactor Function , 2010, Journal of Virology.
[5] Z. Otwinowski,et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35 , 2010, Nature Structural &Molecular Biology.
[6] Gregory R Bowman,et al. Advanced Methods for Accessing Protein Shape-Shifting Present New Therapeutic Opportunities. , 2019, Trends in biochemical sciences.
[7] S. Marqusee,et al. Structural and kinetic mapping of side-chain exposure onto the protein energy landscape , 2011, Proceedings of the National Academy of Sciences.
[8] C. Basler,et al. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus , 2015, Nature Reviews Microbiology.
[9] David K. Johnson,et al. Druggable Protein Interaction Sites Are More Predisposed to Surface Pocket Formation than the Rest of the Protein Surface , 2013, PLoS Comput. Biol..
[10] Michael Proschan,et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.
[11] Kevan M. Shokat,et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.
[12] Dima Kozakov,et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..
[13] H. Feldmann,et al. Post-exposure treatments for Ebola and Marburg virus infections , 2018, Nature Reviews Drug Discovery.
[14] Gregory R Bowman,et al. Cooperative Changes in Solvent Exposure Identify Cryptic Pockets, Switches, and Allosteric Coupling. , 2019, Biophysical journal.
[15] Wei Zhang,et al. A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..
[16] V. Pande,et al. Network models for molecular kinetics and their initial applications to human health , 2010, Cell Research.
[17] M. Schnell,et al. Toward an Effective Ebola Virus Vaccine. , 2017, Annual review of medicine.
[18] Amanda E. Wakefield,et al. Cryptic binding sites on proteins: definition, detection, and druggability , 2018, Current Opinion in Chemical Biology.
[19] R. Stroud,et al. Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[20] Gerrit Groenhof,et al. GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..
[21] J. Nix,et al. Structure of the Ebola VP35 interferon inhibitory domain , 2009, Proceedings of the National Academy of Sciences.
[22] J. Wells,et al. Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.
[23] Frank von Delft,et al. An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering , 2018, eLife.
[24] J R Porter,et al. Enspara: Modeling molecular ensembles with scalable data structures and parallel computing , 2018, bioRxiv.
[25] S. Nichol,et al. Reverse Genetic Generation of Recombinant Zaire Ebola Viruses Containing Disrupted IRF-3 Inhibitory Domains Results in Attenuated Virus Growth In Vitro and Higher Levels of IRF-3 Activation without Inhibiting Viral Transcription or Replication , 2006, Journal of Virology.
[26] Erica Ollmann Saphire,et al. Ebola Virus VP35 Protein Binds Double-Stranded RNA and Inhibits Alpha/Beta Interferon Production Induced by RIG-I Signaling , 2006, Journal of Virology.
[27] Gregory R. Bowman,et al. Prediction of New Stabilizing Mutations Based on Mechanistic Insights from Markov State Models , 2017, ACS central science.
[28] Gregory R Bowman,et al. FAST Conformational Searches by Balancing Exploration/Exploitation Trade-Offs. , 2015, Journal of chemical theory and computation.
[29] Frank Noé,et al. Markov models of molecular kinetics: generation and validation. , 2011, The Journal of chemical physics.
[30] Wei Xu,et al. In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. , 2014, Journal of molecular biology.
[31] Julien Michel,et al. A Collective Variable for the Rapid Exploration of Protein Druggability. , 2015, Journal of chemical theory and computation.
[32] Julie C. Mitchell,et al. CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites. , 2016, Journal of molecular biology.
[33] S. Nichol,et al. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. , 2004, Virology.
[34] Roland Seifert,et al. Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .
[35] Thomas J Lane,et al. MSMBuilder2: Modeling Conformational Dynamics at the Picosecond to Millisecond Scale. , 2011, Journal of chemical theory and computation.
[36] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[37] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[38] Gregory R Bowman,et al. Simulation of spontaneous G protein activation reveals a new intermediate driving GDP unbinding , 2018, bioRxiv.
[39] H. Klenk,et al. The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3 , 2003, Journal of Virology.
[40] Dima Kozakov,et al. Exploring the structural origins of cryptic sites on proteins , 2018, Proceedings of the National Academy of Sciences.
[41] S. Sureshchandra,et al. Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins. , 2016, Cell reports.
[42] Kathryn M Hart,et al. supplementary figures , 2018 .
[43] Heather A Carlson,et al. Moving Beyond Active-Site Detection: MixMD Applied to Allosteric Systems. , 2016, The journal of physical chemistry. B.
[44] E. Saphire,et al. Ebola Virus VP 35 Protein Binds Double-Stranded RNA and Inhibits Alpha / Beta Interferon Production Induced by RIGI Signaling , 2006 .
[45] V. Volchkov,et al. Mutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea Pigs , 2010, Journal of Virology.
[46] Dima Kozakov,et al. FTMAP: extended protein mapping with user-selected probe molecules , 2012, Nucleic Acids Res..
[47] Rommie E. Amaro,et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 , 2013, Nature Communications.
[48] Dima Kozakov,et al. Computational mapping reveals dramatic effect of Hoogsteen breathing on duplex DNA reactivity with formaldehyde , 2012, Nucleic acids research.
[49] Delbert Dueck,et al. Clustering by Passing Messages Between Data Points , 2007, Science.
[50] A. Shrake,et al. Environment and exposure to solvent of protein atoms. Lysozyme and insulin. , 1973, Journal of molecular biology.
[51] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[52] Laurie E. Grove,et al. Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.
[53] G. Bowman,et al. Quantifying Allosteric Communication via Both Concerted Structural Changes and Conformational Disorder with CARDS. , 2017, Journal of chemical theory and computation.
[54] Thomas J Lane,et al. MDTraj: a modern, open library for the analysis of molecular dynamics trajectories , 2014, bioRxiv.
[55] Vijay S. Pande,et al. Everything you wanted to know about Markov State Models but were afraid to ask. , 2010, Methods.
[56] Christopher L. McClendon,et al. Cosolvent-Enhanced Sampling and Unbiased Identification of Cryptic Pockets Suitable for Structure-Based Drug Design. , 2019, Journal of chemical theory and computation.
[57] D. Moir,et al. A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface. , 2017, ACS infectious diseases.
[58] G. Bowman,et al. Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites , 2012, Proceedings of the National Academy of Sciences.
[59] Benjamin P. Cossins,et al. Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations. , 2016, Journal of the American Chemical Society.
[60] Z. Otwinowski,et al. Structural basis for Marburg virus VP35–mediated immune evasion mechanisms , 2012, Proceedings of the National Academy of Sciences.
[61] A. Kozlov,et al. SSB-DNA binding monitored by fluorescence intensity and anisotropy. , 2012, Methods in molecular biology.
[62] Lydia E Kavraki,et al. Quantitative comparison of adaptive sampling methods for protein dynamics. , 2018, The Journal of chemical physics.
[63] Kathryn M Hart,et al. Discovery of multiple hidden allosteric sites by combining Markov state models and experiments , 2015, Proceedings of the National Academy of Sciences.
[64] John Karanicolas,et al. Computational Screening and Design for Compounds that Disrupt Protein-protein Interactions. , 2017, Current topics in medicinal chemistry.
[65] Dima Kozakov,et al. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins , 2015, Nature Protocols.